B-Cell Acute Lymphoblastic Leukemia

90

Pipeline Programs↗

33

Active Trials↗

45

Companies Involved↗

B-cell acute lymphoblastic leukemia is a moderately active landscape with 90 programs across 45 companies. The most active players are Fundamenta Therapeutics, Ltd., Shanghai Pharmaceutical Group Biological Therapy Technology Co., Ltd., Shanghai Ming Ju Biotechnology Co., Ltd.. 1 therapy is approved with 25 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

70/100

Pipeline Velocity

39/100

Mech. Concentration

14/100

Completion Rate

41/100

Attrition Rate

15/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved

Phase 3

Phase 2

Phase 1

Preclinical

Key Players

Top Companies

Fundamenta Therapeutics, Ltd.

2 programs

Shanghai Pharmaceutical Group Biological Therapy Technology Co., Ltd.

1 program

Shanghai Ming Ju Biotechnology Co., Ltd.

1 program

Shanghai Longyao Biotechnology Inc., Ltd.

1 program

Genzyme, a Sanofi Company

1 program

AbbVie

1 program

Analysis

Modality Breakdown

87programs

Small molecule4653%

Cell therapy2428%

Monoclonal antibody910%

Protein / enzyme78%

Antibody–drug conjugate11%

Modality classified for 96% of 106 pipeline programs.

Analysis

Trial Status

67

clinical trials

Recruiting22 · 33%

Unknown status17 · 25%

Completed7 · 10%

Terminated6 · 9%

Not yet recruiting6 · 9%

Active, not recruiting5 · 7%

Other4 · 6%

Clinical Trials

Trial Activity

67 trials

A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)

Recruiting·National Cancer Institute (NCI)·Phase 2·NCT04546399·461 enrolled

Humanized CD19-Specific CAR T Cells for the Treatment of Patients With Positive Relapsed or Refractory CD19 Positive B-Cell Acute Lymphoblastic Leukemia

Recruiting·—·Phase 1·NCT06447987·24 enrolled

Bridging Allogeneic Hematopoietic Stem Cell Transplantation or Not After CD19 CAR - T (S1904) Cell Therapy for r/r B-cell Acute Lymphoblastic Leukemia

Recruiting·PPeking University People's Hospital·N/A·NCT06581081·130 enrolled

Study of KTE-X19 in Minimal Residual Disease (MRD) Positive B-Cell Acute Lymphoblastic Leukemia (B-ALL)

Recruiting·HH. Lee Moffitt Cancer Center and Research Institute·Phase 2·NCT06144606·60 enrolled

Dose-escalation and Dose-expansion Study of Safety of Azer-cel (PBCAR0191) in Participants With Relapsed/Refractory (r/r) Non-Hodgkin Lymphoma (NHL) and r/r B-cell Acute Lymphoblastic Leukemia (B-ALL)

Recruiting·IImugene Limited·Phase 1·NCT03666000·135 enrolled

A Study of Fludarabine Dosing in Children and Young Adults With B-cell Acute Lymphoblastic Leukemia

Recruiting·MMemorial Sloan Kettering Cancer Center·Phase 3·NCT07223021·130 enrolled

A Clinical Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of B019 Injection in Subjects With Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia.

Recruiting·SShanghai Pharmaceutical Group Biological Therapy Technology Co., Ltd.·Phase 1·NCT06927466·33 enrolled

Iomab-ACT: A Pilot Study of 131-I Apamistamab Followed by CD19-Targeted CAR T-Cell Therapy for Patients With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia or Diffuse Large B-Cell Lymphoma

Recruiting·MMemorial Sloan Kettering Cancer Center·Phase 1·NCT04512716·12 enrolled

QH103 Cell Injection for the Treatment of Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia

Recruiting·—·Phase 1·NCT06056752·10 enrolled

KSV01 Injection as the Therapy for Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia

Recruiting·ZZhejiang University·Phase 1·NCT07246707·30 enrolled

A Clinical Study Exploring the Safety, Efficacy and Cell Metabolic Kinetics of Universal Car-t Cell Injection in CD19 and / or CD20 Positive Relapsed / Refractory B-cell Acute Lymphoblastic Leukemia in Adolescents, Children and Adults

Recruiting·UUnion Hospital, Tongji Medical College, Huazhong University of Science and Technology·Phase 1·NCT07470073·18 enrolled

JY231 (JY231) Injection for the Treatment of B-cell Acute Lymphoblastic Leukemia (B-ALL)

Recruiting·—·Phase 1·NCT06514768·20 enrolled

Combination of Inaticabtagene Autoleucel With Autologous Hematopoietic Stem Cell Transplantation for Adolescents or Adults With MRD-Positive B-Cell Acute Lymphoblastic Leukemia in Initial Complete Remission.

Recruiting·IInstitute of Hematology & Blood Diseases Hospital, China·Phase 2·NCT06608732·20 enrolled

A Phase 2 Study to Assess the Safety and Efficacy of Subcutaneous Blinatumomab in Combination With Low Intensity Chemotherapy in Older Patients With Newly Diagnosed B-cell Acute Lymphoblastic Leukemia

Recruiting·MM.D. Anderson Cancer Center·Phase 2·NCT07153796·60 enrolled

Safety and Efficacy of PRG-2302 for Refractory or Relapsed B-cell Acute Lymphoblastic Leukemia Disease.

Recruiting·—·Phase 1·NCT06659653·18 enrolled

Page 1 of 5

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)